BMJ medicine最新文献

{"title":"Multimorbidity in emergency departments: urgent need for integrated care.","authors":"Youri Yordanov, Agathe Beauvais, Pierre-Clément Thiébaud","doi":"10.1136/bmjmed-2024-000989","DOIUrl":"10.1136/bmjmed-2024-000989","url":null,"abstract":"","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive pulmonary fibrosis: a need for real world data to solve real world clinical problems.","authors":"Huajian Liu, Kerri-Marie Heenan, Liam Coyle, Nazia Chaudhuri","doi":"10.1136/bmjmed-2024-000911","DOIUrl":"10.1136/bmjmed-2024-000911","url":null,"abstract":"","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimorbidity and adverse outcomes following emergency department attendance: population based cohort study.","authors":"Michael C Blayney, Matthew J Reed, John A Masterson, Atul Anand, Matt M Bouamrane, Jacques Fleuriot, Saturnino Luz, Marcus J Lyall, Stewart Mercer, Nicholas L Mills, Susan D Shenkin, Timothy S Walsh, Sarah H Wild, Honghan Wu, Stela McLachlan, Bruce Guthrie, Nazir I Lone","doi":"10.1136/bmjmed-2023-000731","DOIUrl":"10.1136/bmjmed-2023-000731","url":null,"abstract":"<p><strong>Abstract: </strong></p><p><strong>Objectives: </strong>To describe the effect of multimorbidity on adverse patient centred outcomes in people attending emergency department.</p><p><strong>Design: </strong>Population based cohort study.</p><p><strong>Setting: </strong>Emergency departments in NHS Lothian in Scotland, from 1 January 2012 to 31 December 2019.</p><p><strong>Participants: </strong>Adults (≥18 years) attending emergency departments.</p><p><strong>Data sources: </strong>Linked data from emergency departments, hospital discharges, and cancer registries, and national mortality data.</p><p><strong>Main outcome measures: </strong>Multimorbidity was defined as at least two conditions from the Elixhauser comorbidity index. Multivariable logistic or linear regression was used to assess associations of multimorbidity with 30 day mortality (primary outcome), hospital admission, reattendance at the emergency department within seven days, and time spent in emergency department (secondary outcomes). Primary analysis was stratified by age (<65 <i>v</i> ≥65 years).</p><p><strong>Results: </strong>451 291 people had 1 273 937 attendances to emergency departments during the study period. 43 504 (9.6%) had multimorbidity, and people with multimorbidity were older (median 73 <i>v</i> 43 years), more likely to arrive by emergency ambulance (57.8% <i>v</i> 23.7%), and more likely to be triaged as very urgent (23.5% <i>v</i> 9.2%) than people who do not have multimorbidity. After adjusting for other prognostic covariates, multimorbidity, compared with no multimorbidity, was associated with higher 30 day mortality (8.2% <i>v</i> 1.2%, adjusted odds ratio 1.81 (95% confidence interval (CI) 1.72 to 1.91)), higher rate of hospital admission (60.1% <i>v</i> 20.5%, 1.81 (1.76 to 1.86)), higher reattendance to an emergency department within seven days (7.8% <i>v</i> 3.5%, 1.41 (1.32 to 1.50)), and longer time spent in the department (adjusted coefficient 0.27 h (95% CI 0.26 to 0.27)). The size of associations between multimorbidity and all outcomes were larger in younger patients: for example, the adjusted odds ratio of 30 day mortality was 3.03 (95% CI 2.68 to 3.42) in people younger than 65 years versus 1.61 (95% CI 1.53 to 1.71) in those 65 years or older.</p><p><strong>Conclusions: </strong>Almost one in ten patients presenting to emergency department had multimorbidity using Elixhauser index conditions. Multimorbidity was strongly associated with adverse outcomes and these associations were stronger in younger people. The increasing prevalence of multimorbidity in the population is likely to exacerbate strain on emergency departments unless practice and policy evolve to meet the growing demand.</p>","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All cause and cause specific mortality in 15-24-year-olds in Denmark 2010 to 2022: nationwide study of socioeconomic predictors.","authors":"Sofie Kruckow, Janne S Tolstrup","doi":"10.1136/bmjmed-2023-000685","DOIUrl":"10.1136/bmjmed-2023-000685","url":null,"abstract":"<p><strong>Objective: </strong>To assess inequalities in all cause and cause specific mortality in young people and if there are differences across gender and age groups.</p><p><strong>Design: </strong>Nationwide cohort study of socioeconomic predictors.</p><p><strong>Setting: </strong>Denmark, 1 January 2010 to 31 December 2022.</p><p><strong>Participants: </strong>All Danes of ages 15 to 24 years during the study period summing to a total of 9 314 807 person years and 2297 deaths. Participant and parental information were linked to obtain information on socioeconomic background to investigate differences in parents' educational level, employment status, and family's disposable income, using annually updated nationwide registers.</p><p><strong>Main outcome measures: </strong>All cause and cause specific mortality including natural deaths (ie, medical conditions and diseases) and unnatural deaths (accidents, suicides, and homicides). Poisson regression was used to calculate incidence rate ratios and 95% confidence intervals (CI).</p><p><strong>Results: </strong>Overall mortality rate was 24.7 (95% CI 23.7 to 25.7) and higher for men (33.2 (31.5 to 34.8)) compared with women (15.8 (14.6 to 16.9)). All cause and cause specific mortality were higher in financially disadvantaged groups compared with more affluent groups, and consistently so for all three measures of socioeconomic position. Results generally reflected a dose dependent association showing a higher mortality with lower levels of socioeconomic position. For instance, incidence rate ratios of all cause mortality related to parents' education was 2.3 (95% CI 2.0 to 2.7) for elementary level, 1.5 (1.3 to 1.6) for low, and 1.3 (1.1 to 1.4) for medium level as compared with high level. For deaths, incidence rate ratios of elementary education level compared with the most well educated group were 2.2 (1.5 to 3.2) for natural causes, 3.3 (2.5 to 4.4) for accidents, 1.6 (1.2 to 2.2) for suicides, and 3.1 (0.8 to 12) for homicides. Associations were similar in strata of men and women and by age group (15-17 <i>v</i> 18-24 years). Mortality in young men was considerably higher than in young women for all of the causes.</p><p><strong>Conclusion: </strong>Young people from disadvantaged backgrounds have a markedly higher mortality from all causes than those from more affluent families. The socioeconomic position of their parents was associated with premature mortality in a dose dependent manner meaning that this effect is not only a concern for marginalised groups. Public health attention should be directed to respond to these inequities by strengthening advocacy for adolescent health, ensuring focus on adolescents in health policies and strategies, using the response to adolescent health as an indicator of equity, and prioritising research into the underlying mechanisms linking socioeconomic position in adolescence and mortality.</p>","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a prognostic model to predict birth weight: individual participant data meta-analysis.","authors":"John Allotey, Lucinda Archer, Kym I E Snell, Dyuti Coomar, Jacques Massé, Line Sletner, Hans Wolf, George Daskalakis, Shigeru Saito, Wessel Ganzevoort, Akihide Ohkuchi, Hema Mistry, Diane Farrar, Fionnuala Mone, Jun Zhang, Paul T Seed, Helena Teede, Fabricio Da Silva Costa, Athena P Souka, Melanie Smuk, Sergio Ferrazzani, Silvia Salvi, Federico Prefumo, Rinat Gabbay-Benziv, Chie Nagata, Satoru Takeda, Evan Sequeira, Olav Lapaire, Jose Guilherme Cecatti, Rachel Katherine Morris, Ahmet A Baschat, Kjell Salvesen, Luc Smits, Dewi Anggraini, Alice Rumbold, Marleen van Gelder, Arri Coomarasamy, John Kingdom, Seppo Heinonen, Asma Khalil, François Goffinet, Sadia Haqnawaz, Javier Zamora, Richard D Riley, Shakila Thangaratinam, Alex Kwong, Ary I Savitri, Sohinee Bhattacharya, Cuno Spm Uiterwaal, Annetine C Staff, Louise Bjoerkholt Andersen, Elisa Llurba Olive, Christopher Redman, Maureen Macleod, Baskaran Thilaganathan, Javier Arenas Ramírez, Francois Audibert, Per Minor Magnus, Anne Karen Jenum, Fionnuala M McAuliffe, Jane West, Lisa M Askie, Peter A Zimmerman, Catherine Riddell, Joris van de Post, Sebastián E Illanes, Claudia Holzman, Sander M J van Kuijk, Lionel Carbillon, Pia M Villa, Anne Eskild, Lucy Chappell, Luxmi Velauthar, Miriam van Oostwaard, Stefan Verlohren, Lucilla Poston, Enrico Ferrazzi, Christina A Vinter, Mark Brown, Karlijn C Vollebregt, Josje Langenveld, Mariana Widmer, Camilla Haavaldsen, Guillermo Carroli, Jørn Olsen, Nelly Zavaleta, Inge Eisensee, Patrizia Vergani, Pisake Lumbiganon, Maria Makrides, Fabio Facchinetti, Marleen Temmerman, Robert Gibson, Tiziana Frusca, Jane E Norman, Ernesto A Figueiró-Filho, Hannele Laivuori, Jacob A Lykke, Agustin Conde-Agudelo, Alberto Galindo, Alfred Mbah, Ana Pilar Betran, Ignacio Herraiz, Lill Trogstad, Gordon G S Smith, Eric A P Steegers, Read Salim, Tianhua Huang, Annemarijne Adank, Wendy S Meschino, Joyce L Browne, Rebecca E Allen, Kerstin Klipstein-Grobusch, Caroline A Crowther, Jan Stener Jørgensen, Jean-Claude Forest, Ben W Mol, Yves Giguère, Louise C Kenny, Anthony O Odibo, Jenny Myers, SeonAe Yeo, Lesley McCowan, Eva Pajkrt, Bassam G Haddad, Gustaaf Dekker, Emily C Kleinrouweler, Édouard LeCarpentier, Claire T Roberts, Henk Groen, Ragnhild Bergene Skråstad, Kajantie Eero, Athanasios Pilalis, Renato T Souza, Lee Ann Hawkins, Francesc Figueras, Francesca Crovetto","doi":"10.1136/bmjmed-2023-000784","DOIUrl":"10.1136/bmjmed-2023-000784","url":null,"abstract":"<p><strong>Objective: </strong>To predict birth weight at various potential gestational ages of delivery based on data routinely available at the first antenatal visit.</p><p><strong>Design: </strong>Individual participant data meta-analysis.</p><p><strong>Data sources: </strong>Individual participant data of four cohorts (237 228 pregnancies) from the International Prediction of Pregnancy Complications (IPPIC) network dataset.</p><p><strong>Eligibility criteria for selecting studies: </strong>Studies in the IPPIC network were identified by searching major databases for studies reporting risk factors for adverse pregnancy outcomes, such as pre-eclampsia, fetal growth restriction, and stillbirth, from database inception to August 2019. Data of four IPPIC cohorts (237 228 pregnancies) from the US (National Institute of Child Health and Human Development, 2018; 233 483 pregnancies), UK (Allen et al, 2017; 1045 pregnancies), Norway (STORK Groruddalen research programme, 2010; 823 pregnancies), and Australia (Rumbold et al, 2006; 1877 pregnancies) were included in the development of the model.</p><p><strong>Results: </strong>The IPPIC birth weight model was developed with random intercept regression models with backward elimination for variable selection. Internal-external cross validation was performed to assess the study specific and pooled performance of the model, reported as calibration slope, calibration-in-the-large, and observed versus expected average birth weight ratio. Meta-analysis showed that the apparent performance of the model had good calibration (calibration slope 0.99, 95% confidence interval (CI) 0.88 to 1.10; calibration-in-the-large 44.5 g, -18.4 to 107.3) with an observed versus expected average birth weight ratio of 1.02 (95% CI 0.97 to 1.07). The proportion of variation in birth weight explained by the model (R²) was 46.9% (range 32.7-56.1% in each cohort). On internal-external cross validation, the model showed good calibration and predictive performance when validated in three cohorts with a calibration slope of 0.90 (Allen cohort), 1.04 (STORK Groruddalen cohort), and 1.07 (Rumbold cohort), calibration-in-the-large of -22.3 g (Allen cohort), -33.42 (Rumbold cohort), and 86.4 g (STORK Groruddalen cohort), and observed versus expected ratio of 0.99 (Rumbold cohort), 1.00 (Allen cohort), and 1.03 (STORK Groruddalen cohort); respective pooled estimates were 1.00 (95% CI 0.78 to 1.23; calibration slope), 9.7 g (-154.3 to 173.8; calibration-in-the-large), and 1.00 (0.94 to 1.07; observed <i>v</i> expected ratio). The model predictions were more accurate (smaller mean square error) in the lower end of predicted birth weight, which is important in informing clinical decision making.</p><p><strong>Conclusions: </strong>The IPPIC birth weight model allowed birth weight predictions for a range of possible gestational ages. The model explained about 50% of individual variation in birth weights, was well calibrated (especiall","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting birth weight at booking.","authors":"Emily Prior, Sabita Uthaya","doi":"10.1136/bmjmed-2024-001018","DOIUrl":"10.1136/bmjmed-2024-001018","url":null,"abstract":"","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age and sex specific thresholds for risk stratification of cardiovascular disease and clinical decision making: prospective open cohort study.","authors":"Zhe Xu, Juliet Usher-Smith, Lisa Pennells, Ryan Chung, Matthew Arnold, Lois Kim, Stephen Kaptoge, Matthew Sperrin, Emanuele Di Angelantonio, Angela M Wood","doi":"10.1136/bmjmed-2023-000633","DOIUrl":"10.1136/bmjmed-2023-000633","url":null,"abstract":"<p><strong>Objective: </strong>To quantify the potential advantages of using 10 year risk prediction models for cardiovascular disease, in combination with risk thresholds specific to both age and sex, to identify individuals at high risk of cardiovascular disease for allocation of statin treatment.</p><p><strong>Design: </strong>Prospective open cohort study.</p><p><strong>Setting: </strong>Primary care data from the UK Clinical Practice Research Datalink GOLD, linked with hospital admissions from Hospital Episode Statistics and national mortality records from the Office for National Statistics in England, 1 January 2006 to 31 May 2019.</p><p><strong>Participants: </strong>1 046 736 individuals (aged 40-85 years) with no cardiovascular disease, diabetes, or a history of statin treatment at baseline using data from electronic health records.</p><p><strong>Main outcome measures: </strong>10 year risk of cardiovascular disease, calculated with version 2 of the QRISK cardiovascular disease risk algorithm (QRISK2), with two main strategies to identify individuals at high risk: in strategy A, estimated risk was a fixed cut-off value of ≥10% (ie, as per the UK National Institute for Health and Care Excellence guidelines); in strategy B, estimated risk was ≥10% or ≥90th centile of age and sex specific risk distributions.</p><p><strong>Results: </strong>Compared with strategy A, strategy B stratified 20 241 (149.8%) more women aged ≤53 years and 9832 (150.2%) more men aged ≤47 years as having a high risk of cardiovascular disease; for all other ages the strategies were the same. Assuming that treatment with statins would be initiated in those identified as high risk, differences in the estimated gain in cardiovascular disease-free life years from statin treatment for strategy B versus strategy A were 0.14 and 0.16 years for women and men aged 40 years, respectively; among individuals aged 40-49 years, the numbers needed to treat to prevent one cardiovascular disease event for strategy B versus strategy A were 39 versus 21 in women and 19 versus 15 in men, respectively.</p><p><strong>Conclusions: </strong>This study quantified the potential gains in cardiovascular disease-free life years when implementing prevention strategies based on age and sex specific risk thresholds instead of a fixed risk threshold for allocation of statin treatment. Such gains should be weighed against the costs of treating more younger people with statins for longer.</p>","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies","authors":"Jennifer Miller, William Pelletiers, Sakinah C. Suttiratana, Michael Ofosu Mensah, Jason Schwartz, Reshma Ramachandran, Cary Gross, Joseph S. Ross","doi":"10.1136/bmjmed-2024-000920","DOIUrl":"https://doi.org/10.1136/bmjmed-2024-000920","url":null,"abstract":"To develop a reference standard based on US Food and Drug Administration and stakeholder guidance for pharmaceutical companies' policies on diversity in clinical trials and to assess these policies.Development of a reference standard and structured audit for clinical trial diversity policies.50 pharmaceutical companies selected from the top 500 by their market capitalizations in 2021 (the 25 largest companies and 25 non-large companies, randomly selected from the remaining 475 companies).Data from pharmaceutical company websites and annual reports. Policy guidance from the Pharmaceutical Research and Manufacturers of America, International Federation of Pharmaceutical Manufacturers and Associations, Biotechnology Industry Organization, International Committee of Medical Journal Editors, the US Food and Drug Administration, European Medicines Agency, and World Health Organization, up to 15 May 2023.Multicomponent measure based on distinct themes derived from FDA and stakeholder guidance.Reviewing FDA and stakeholder guidance identified 14 distinct themes recommended for improving diversity in clinical trials, which were built into a reference standard: (1) enrollment targets that reflect the prevalence of targeted conditions in populations, (2) broad eligibility criteria for trials, (3) diversity in the workforce, (4) identification and remedy of barriers to trial recruitment and retention, (5) incorporation of patient input into trial design, (6) health literacy, (7) multidimensional approaches to diversity, (8) sites with diverse providers and patient populations, (9) data collection after product approval, (10) diverse enrollment in every country where trials are conducted, (11) diverse enrollment should be a focus for all phases of clinical trials, not just later stage or pivotal trials, (12) varied trial design, (13) expanded access, and (14) public reporting of the personal characteristics of participants in trials. Applying this reference standard, 48% (24/50) of companies had no public policy on diversity in clinical trials; among those with policies, content varied widely. Large companies were more likely to have a public policy than non-large companies (21/25, 84%v5/25, 20%, P<0.001). Large companies most frequently committed to using epidemiological based trial enrollment targets representing the prevalence of indicated conditions in various populations (n=15, 71%), dealing with barriers to trial recruitment (n=15, 71%), and improving patient awareness of trial opportunities (n=14, 67%). The location of the company was not associated with having a public diversity policy (P=0.17). The average company policy had five of the 14 commitments (36%, range 0-8) recommended in FDA and stakeholder guidance.The findings of the study showed that many pharmaceutical companies did not have public policies on diversity in clinical trials, although policies were more common in large than non-large companies. Policies that were publicly available varie","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141716180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fostering diversity in clinical trials: need for evidence and implementation to improve representation","authors":"David Collister, Claire Song, S. Ruzycki","doi":"10.1136/bmjmed-2024-000984","DOIUrl":"https://doi.org/10.1136/bmjmed-2024-000984","url":null,"abstract":"","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141698393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the methodological quality and risk of bias of systematic reviews: primer for authors of overviews of systematic reviews.","authors":"Carole Lunny, Salmaan Kanji, Pierre Thabet, Anna-Bettina Haidich, Konstantinos I Bougioukas, Dawid Pieper","doi":"10.1136/bmjmed-2023-000604","DOIUrl":"10.1136/bmjmed-2023-000604","url":null,"abstract":"","PeriodicalId":72433,"journal":{"name":"BMJ medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141201463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}